Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 90 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?. Hellenic J Cardiol. 50(2), 89-91.
Athyros, V. G., Katsiki N., Karagiannis A., & Radak D. (2014).  Effect of Statins on rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy.. Curr Vasc Pharmacol.
Athyros, V. G., Kakafika A., Karagiannis A., & Mikhailidis D. P. (2007).  Statins and regression of coronary atherosclerosis.. JAMA. 297(20), 2197; author reply 2197.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Lipid-lowering agents and new onset diabetes mellitus.. Expert Opin Pharmacother. 11(12), 1965-70.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Paraskevas K. I., Tziomalos K., Anagnostis P., et al. (2008).  Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.. Curr Med Res Opin. 24(6), 1593-9.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 10(3), 374-7.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention.. Circ J. 77(5), 1348.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Off target effects of statins shape total mortality?. J Drug Assess. 5(1), 4-5.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Treating heart failure with preserved ejection fraction: statins could make the difference.. Angiology. 65(4), 328-9.
Athyros, V. G., Ganotakis E. S., Elisaf M. S., Liberopoulos E. N., Goudevenos I. A., & Karagiannis A. (2007).  Prevalence of vascular disease in metabolic syndrome using three proposed definitions.. Int J Cardiol. 117(2), 204-10.
Athyros, V. G., Tziomalos K., Florentin M., Karagiannis A., & Mikhailidis D. P. (2010).  Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. Curr Med Res Opin. 26(4), 839-42.
Athyros, V. G., Tziomalos K., Gossios T. D., Griva T., Anagnostis P., Kargiotis K., et al. (2010).  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.. Lancet. 376(9756), 1916-22.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention.. Curr Med Res Opin. 31(2), 191-5.
Athyros, V. G., Tziomalos K., Kakafika A. I., Koumaras H., Karagiannis A., & Mikhailidis D. P. (2008).  Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.. Am J Cardiol. 101(4), 483-5.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές